Stellar Biotechnologies Acquires Exclusive, Worldwide License to Clostridium Difficile Immunotherapy Technology
July 30, 2013 09:05 ET
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Jul 30, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has acquired the...
Stellar Biotechnologies Announces Joint Research on Clostridium Difficile Immunotherapy Accepted for Presentation
July 24, 2013 18:01 ET
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - Jul 24, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that a preclinical abstract on...
Stellar Biotechnologies Presents at Annual 2013 National Science Foundation Conference
May 28, 2013 09:00 ET
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - May 28, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at...
Stellar Biotechnologies Announces Publication of "Expert Review" Article on Clostridium Difficile Vaccines
April 30, 2013 09:00 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Apr 30, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole...
Stellar Biotechnologies Submits Biological Master File to U.S. FDA for Subunit KLH
March 19, 2013 09:15 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Mar 19, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of...
Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting
May 11, 2012 08:52 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
With Final Review of Phase IIb Viral Load Data Completed, Researchers Confirm Statistically Significant Reduction of HIV Viral Load on Vacc-4x Compared to Placebo
February 15, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Feb 15, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Final review of phase IIb data confirms statistically significant 64%...
VIRxSYS Issued Third U.S. Patent This Year for Its Spliceosome-Mediated RNA Trans-Splicing (SMaRT(TM)) Program; Breakthrough RNA Therapeutic Platform
September 22, 2011 08:00 ET
|
VIRxSYS Corporation
GAITHERSBURG, MD--(Marketwire - Sep 22, 2011) - VIRxSYS Corporation, a Maryland-based biotechnology company, today announced that the United States Patent and Trademark Office has issued a third...
Researchers to Present Results From Two VIRxSYS HIV Studies at the 6th International AIDS Society Meeting
June 28, 2011 10:06 ET
|
VIRxSYS Corporation
GAITHERSBURG, MD--(Marketwire - Jun 28, 2011) - VIRxSYS Corporation today announced that data from two HIV studies will be presented at the 6th International AIDS Society Conference on HIV...
Elysium Internet, Inc. Closes Acquisition of Health-Related Internet Directory Business
July 24, 2007 08:00 ET
|
FTS Group, Inc.
TAMPA, FL--(Marketwire - July 24, 2007) - FTS Group, Inc. (OTCBB: FLIP), an acquisition and
development Company operating in the Internet, Wireless and Technology
space, today announced that...